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Background: The aim of this study was to evaluate whether slow injection of diluted rocuronium could reduce 
rocuronium-induced withdrawal movements effectively in children. 
Methods: After loss of consciousness, rocuronium 0.6 mg/kg was administered into 171 children according to the 
pre-assigned groups as follows: Group CF, injection of non-diluted rocuronium over 5 seconds; Group CS, injection 
of non-diluted rocuronium over 1 minute; Group DF, injection of diluted rocuronium (10 times) over 5 seconds; 
Group DS, injection of diluted rocuronium over 1 minute. An investigator who was blind to the injection techniques 
recorded patient movements followed by rocuronium injection. 
Results: The incidence of withdrawal movement in Group CF was highest among the groups (all P < 0.0001). 
Moreover, withdrawal movement was less frequently observed in Group DS than in Groups CS and DF (P = 0.021 and 
P = 0.007, respectively). 
Conclusions: Slow injection of diluted rocuronium reduced the incidence of withdrawal movements in children. 
(Korean J Anesthesiol 2011; 61: 465-469)
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Introduction
Rocuronium is frequently used to facilitate tracheal intu-
bation during the induction of general anesthesia. However, 
rocuronium injections often produce withdrawal movements 
of the injected periphery or generalized movement related 
to injection pain [1-3]. Although there is no report of recall or 
complaint of rocuronium-related pain after anesthetic recovery, 
extreme movement during the induction of anesthesia can 
be potentially harmful to patients, especially in children. 
There was a case of pulmonary aspiration secondary to gastric 
regurgitation caused by generalized movement during rocu-
ronium injection [4]. In addition, these rocuronium-related 
withdrawal movements appeared to occur more frequently in 
younger patients [5].
Numerous studies have reported various techniques to mitigate 
withdrawal movements during rocuronium injection including 
the use of drugs [5-12], dilution with 0.9% NaCl [13], and slow 
infusion by a syringe pump [14]. However, these methods 
often require additional materials which seem cumbersome in 
the clinical settings. The aim of this prospective, randomized, 
and double-blinded study was to evaluate whether it was 
possible to reduce withdrawal movements to a similar degree 
observed in previously reported methods on pediatric patients 
using a combination of simple dilution and slow injection of 
rocuronium.
Materials and Methods
After obtaining our institutional review board approval (Ref: 
2008-12-038-001) and written informed consent, a total of 171 
American Society of Anesthesiologists (ASA) physical status 
I or II patients, aged 1-15 years that were undergoing general 
anesthesia for elective surgery were enrolled in this study. The 
CONSORT guidelines were followed with respect to the reporting 
of this prospective, randomized, and double-blinded study. 
Rocuronium was approved by FDA for pediatric administration 
(0.6 mg/kg) as an adjunct to general anesthesia to facilitate 
tracheal intubation (http://www.accessdata.fda.gov/
drugsatfda_docs/label/2008/020214s030lbl.pdf). Patients with 
a history of neurologic deficit, known allergy to the trial drug, 
or asthma, and those who had received analgesics or sedative 
within the previous 24 hours were excluded from this study. 
Patients were randomized using an internet-based computer 
program (http://www.randomizer.org) to one of four groups 
as follows: Group CF (n = 43), fast injection over 5 seconds of 
non-diluted rocuronium (10 mg/ml); Group CS (n = 40), slow 
injection over 1 minute of non-diluted rocuronium (10 mg/
ml); Group DF (n = 42), fast injection over 5 seconds of diluted 
rocuronium with maintaining solution (1 mg/ml); Group DS (n 
= 46), slow injection over 1 minute of diluted rocuronium with 
maintaining solution (1 mg/ml). Identical syringes were used 
for all injections.
No premedication was administered before surgery. In the 
wards, a 24-gauge intravenous cannula was inserted in one of 
either dorsum of the hands. Upon arrival in the operating room, 
clinical standard monitoring including electrocardiography, 
pulse oxymetry, and non-invasive blood pressure measurement 
were applied. In Group DF and Group DS, rocuronium was 
diluted using the maintaining intravenous solution (0.9% 
NaCl or Ringer’s lactate solution) when patients arrived in the 
operating room. All syringes were prepared by an investigator 
and were covered to hide the nature and amount of the solution. 
Anesthesia was induced with 2.5% thiopental sodium 
(5 mg/kg body weight). After the loss of consciousness was 
confirmed by abolished eyelash reflex, mask ventilation with 2 
vol% seveoflurane in oxygen was started. Rocuronium 0.6 mg/
kg was administered according to the pre-assigned group into 
a rubber port connected directly to the intravenous cannula 
after end-tidal concentration of sevoflurane reached 2 vol%. In 
all patients, the investigator kept hold of the prepared syringe 
for over 1 minute to prevent the observer from knowing the 
duration of the rocuronium injection. In addition, the injection 
was performed under the surgical table in all enrolled patients. 
The flow of the intravenous fluid was maintained at a rate 
of 5-7 ml/min during the study period. No other drug was 
administered until completing the injection of rocuronium. 
The blinded observer stood outside the operating room 
during the preparation of the syringe and assessed patient 
response during and immediately after rocuronium injection. 
The movement related to rocuronium injection was graded 
according to the four-point scale [3]: 1 = no response, 2 = move-
ment at the wrist only, 3 = movement involving the arm only 
(elbow or shoulder), and 4 = generalized movement or with-
drawal in more than one extremity. A grade ≥2 was considered 
as significant movement.
To detect a 50%-difference in the incidence of rocuronium-
induced withdrawal movement, at least 32 patients per group 
were required at a significant level of 0.05 and a probability 
power of 0.8 based on the estimated incidence of 80%. Data 
were presented as mean ± SD or number of patients. Patient 
characteristics were compared by one-way analysis of variance 
or chi-square test, when indicated. The incidence of withdrawal 
response was analyzed using the Fisher’s exact test. The 
Kruskal-Wallis test was used to compare the grade of movement 
and the multiple comparisons among groups were analyzed by 
the Mann-Whitney U test with Bonferroni’s correction. SPSS 
12.0 for Window (SPSS Inc., Chicago, IL, USA) was used for 
all statistical analysis. A P < 0.05 was considered statistically 
significant.467 www.ekja.org
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Results
A total of 171 pediatric patients were enrolled in this study 
from June 2008 to March 2011. No patient was excluded 
from the study. There was no significant difference in patient 
characteristics among the different groups (Table 1) and there 
was no complication related to the study. 
The overall incidences of withdrawal movement related to 
rocuronium injection in Groups CF, CS, DF and DS were 95.3%, 
47.5%, 50.0% and 21.7%, respectively (Fig. 1). The incidences 
of withdrawal response in Groups CS, DF and DS were less 
frequent than that of Group CF (all P < 0.0001) (Fig. 1). In 
addition, the incidence of withdrawal movement in Group DS 
was significantly less frequent than those in Groups CS and 
DF (P = 0.021 and P = 0.007, respectively) (Fig. 1). Moreover, 
after multiple comparisons of the four groups, slow injection of 
diluted rocuronium was the most effective to reduce the grade 
of withdrawal movement (Table 2). There was no difference 
in reducing withdrawal response between the slow injection 
technique of undiluted rocuronium and fast injection technique 
of diluted rocuronium (Table 2). However, those two techniques 
were still more effective than the fast injection technique using 
undiluted rocuronium (Table 2).
Discussion
Our study showed that the combination of manual slow 
injection and simple dilution of rocuronium was effective in 
decreasing the incidence of withdrawal movement followed by 
rocuronium injection in pediatric patients.
The exact cause of rocuronium injection-induced withdrawal 
movement has not been elucidated, but the elicitation of 
pain has been ascribed as one of the important factors [2,3]. 
Several possible mechanisms of rocuronium-induced pain by 
Fig. 1. Overall incidence of the withdrawal movements related to 
rocuronium injection. Group CF: fast injection over 5 seconds of 
non-diluted rocuronium (10 mg/ml), Group CS: slow injection over 
1 minute of non-diluted rocuronium (10 mg/ml), Group DF: fast 
injection over 5 seconds of diluted rocuronium with maintaining 
solution (1 mg/ml), Group DS: slow injection over 1 minute of 
diluted rocuronium with maintaining solution (1 mg/ml). Values are 
number of patients (% incidence), which are displayed in the middle 
of bars. *P < 0.0001 versus Group CF. 
†P = 0.021 versus Group CS. 
‡P = 0.007 versus Group DF.
Table 1. Characteristics of Patients in this Study
Group CF (n = 43) Group CS (n = 40) Group DF (n = 42) Group DS (n = 46)
Age (yr)
Weight (kg)
Male/Female
6.1 (4.2)
25.1 (15.9)
36/7
7.1 (4.5)
28.6 (17.0)
28/12
6.8 (3.7)
27.2 (15.6)
28/14
6.4 (4.2)
28.2 (16.1)
33/13
Values are means (SD) or numbers of patients. Group CF: fast injection over 5 seconds of non-diluted rocuronium (10 mg/ml), Group CS: slow 
injection over 1 minute of non-diluted rocuronium (10 mg/ml), Group DF: fast injection over 5 seconds of diluted rocuronium with maintaining 
solution (1 mg/ml), Group DS: slow injection over 1 minute of diluted rocuronium with maintaining solution (1 mg/ml).  There is no difference 
among the groups.
Table 2. Grade of Withdrawal Movement Related to Rocuronium Injection
Group CF (n = 43) Group CS* (n = 40) Group DF* (n = 42) Group DS*
,†,‡ (n = 46)
1 (no response)
2 (wrist)
3 (elbow/shoulder)
4 (generalized)
2 (4.7)
3 (7.0)
10 (23.3)
28 (65.1)
21 (52.5)
11 (27.5)
7 (17.5)
1 (2.5)
21 (50.0)
11 (26.2)
7 (16.7)
3 (7.1)
36 (78.3)
8 (17.3)
1 (2.2)
1 (2.2)
Values are number of patients (% incidence). Group CF: fast injection over 5 seconds of non-diluted rocuronium (10 mg/ml), Group CS: slow 
injection over 1 minute of non-diluted rocuronium (10 mg/ml), Group DF: fast injection over 5 seconds of diluted rocuronium with maintaining 
solution (1 mg/ml), Group DS: slow injection over 1 minute of diluted rocuronium with maintaining solution (1 mg/ml).  The movements 
followed by rocuronium injection were graded according to the four-point scale: 1 = no response, 2 = movement at the wrist only, 3 = movement 
involving the arm only (elbow or shoulder), and 4 = generalized movement or withdrawal in more than one extremity.  *P < 0.01 versus Group 
CF. 
†P < 0.05 versus Group CS.  
‡P < 0.05 versus Group DS.  All P values were adjusted by Bonferroni’s correction.468 www.ekja.org
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activation of nociceptors include: 1) by the un-physiological 
osmolality or low pH of rocuronium solution, 2) by the release 
of endogenous mediators, such as histamine or bradykinin, 
or 3) by the allogenic effect of aminosteroidal neuromuscular 
blocking drugs [2,6,9]. However, regardless of its mechanism, 
the prevention of withdrawal movements during rocuronium 
injection is especially important in pediatric patients because 
severe movement can easily dislodge the intravenous cannula 
and re-cannulation itself is a time-consuming and sometimes 
very difficult procedure because of tiny vessels and extensive 
subcutaneous fat tissue. In addition, if the condition of the 
patient is unstable, dislodgement of intravenous cannula 
and the delay of re-cannulation would be very harmful to 
the patients. Moreover, especially in pediatric patients, the 
generalized movement itself could be fatal because it can cause 
pulmonary aspiration following gastric regurgitation [4]. 
To reduce withdrawal movements induced by rocuronium 
injection, various techniques have been introduced. However, 
all previous methods need additional drugs [7,10-12,15-
17], mixing solutions [13,18], and devices [14], which are not 
essentially required during general anesthesia induction. In 
addition, mixing different drugs and increasing the number 
of administered drugs may be potentially problematic [19]. 
Compared to the previously described techniques, our 
combination technique appears to be more practical in clinical 
settings because it does not require any additional device, 
drugs, or solutions. In fact, all materials which we used in 
this study were essentially needed for rocuronium injection. 
Moreover, our technique can be modified to simple slow 
injection of rocuronium through fully-dripped maintaining 
intravenous solution in clinical anesthesia.
Our injection protocol was derived from two previous 
techniques including dilution of rocuronium with 0.9% NaCl 
[13] and slow infusion of rocuronium using a syringe pump [14]. 
However, those studies are different form our study because the 
category of patients in those studies were only adults and they 
showed higher incidences of withdrawal movements than the 
subjects in our study [1,2]. 
Overall incidence of withdrawal movement in our patients 
who underwent the combination technique (Group DS) was 
21.7%. The result was similar with the previous study [8] where 
the incidence was 23% using pretreatment of remifentanil in 
children. The comparable outcomes between the two studies 
suggest that our combination technique may be considered 
as more clinically applicable in pediatric patients. In addition, 
the overall incidence of withdrawal movement related to 
rocuronium injection was 95.3% in the control group (Group 
CF). This result was also consistent with the previous results 
where the incidence was 83 to 100% [3,9,14,20]. Although the 
simple dilution technique (Group DF) in our study showed a 
higher incidence of withdrawal movement than in the previous 
study [13] where diluted rocuronium with 0.9% NaCl was 
applied in adults, this result may be caused by the relatively low 
incidence of withdrawal movement in adult patients, compared 
with pediatric patients [10,21]. 
There are several limitations in this study. First, pH of 
diluted rocuronium was not measured. However, it was already 
suggested that pH 4-adjusted saline did not trigger the injection 
pain in previous studies [2]. Moreover, Tuncali et al. [13] 
reported that the dilution of rocuronium with 0.9% NaCl did not 
change its pH and osmolality. Therefore, we believed that the 
pH of our diluted solution had little effect on the results of this 
study. Second, we did not apply our technique to adult patients. 
Considering the low incidence (12 to 28%) of withdrawal 
movement related to rocuronium injection in adults [10,21], the 
results may be different from our results in children. Further 
studies are needed to evaluate the effect of our technique in 
adult patients. Third, the injection speed of rocuronium was 
divided as fast or slow based on the injection time without 
considering the total amount of rocuronium. In addition, the 
speed of rocuronium injection may be inconsistent because 
we did not use any device to assess it. Those two confounding 
factors would affect the results in this study. However, the aim 
of this study was to find the simplest technique to decrease 
withdrawal movement during rocuronium injection. Therefore, 
our manual slow injection technique using diluted rocuronium 
may not be precise and warrant further investigation, but it still 
appears to be clinically usable. Lastly, we did not compare our 
technique to the various reported methods using different drugs 
directly. However, the incidence of withdrawal movements in 
our simple technique (Group DS) was in accordance with the 
previous study which used remifentanil in children. Therefore, 
we believed that our technique had a similar effect of reducing 
the incidence of withdrawal movement, compared with 
previous methods. 
In conclusion, our manual slow injection of diluted rocuro-
nium could significantly reduce the incidence of withdrawal 
movement to a similar degree reported previously in pediatric 
patients. Therefore, we recommend our method as a daily 
usable technique of rocuronium injection for reducing with-
drawal movement in pediatric patients because of its simplicity 
and availability.
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